drugset / Trial / NCT00424294

A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis

NCT00424294

Phase 2 Terminated 70 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy, safety and tolerability of CP-195543 and celecoxib dual therapy in subjects with rheumatoid arthritis

Timeline

Start
2006-06
Primary completion
2007-12
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject CP-195543 Small molecule
Comparator Celecoxib Other / unclassified
Background Methotrexate Small molecule

Indications